scholarly journals Faculty Opinions recommendation of Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?

Author(s):  
Norah Terrault
2014 ◽  
Vol 3 (3) ◽  
pp. 289 ◽  
Author(s):  
Sakthivel Selvaraj ◽  
Indranil Mukhopadhyay ◽  
Preeti Kumar ◽  
Malini Aisola ◽  
Pritam Datta ◽  
...  

AIDS ◽  
2020 ◽  
Vol 34 (9) ◽  
pp. 1347-1358
Author(s):  
Samira Hosseini-Hooshyar ◽  
Marianne Martinello ◽  
Jasmine Yee ◽  
Phillip Read ◽  
David Baker ◽  
...  

2020 ◽  
Vol 73 ◽  
pp. S313
Author(s):  
Yu Jun Wong ◽  
Fria May Gloriba Manejero ◽  
Kim Wei Lim ◽  
Sin Yoong Chong ◽  
Linn War Mai ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Iara Fabricia Kretzer ◽  
Andrea do Livramento ◽  
Joel da Cunha ◽  
Sabrina Gonçalves ◽  
Iraci Tosin ◽  
...  

Hepatitis C virus (HCV) is endemic worldwide and according to the World Health Organization (WHO), there are about 150 million chronic carriers worldwide. The infection is a leading cause of liver diseases like cirrhosis and hepatocellular carcinoma (HCC); thus, HCV infection constitutes a critical public health problem. There are increasing efforts worldwide in order to reduce the global impact of hepatitis C through the implementation of programmatic actions that may increase the awareness of viral hepatitis and also improve surveillance, prevention, and treatment. In Brazil, about 1,5 million people have been chronically infected with HCV. The country has a vast territory with uneven population density, and hepatitis C incidence rates are variable with the majority of cases concentrated in the most populated areas. Currently, the main priorities of Brazilian Ministry of Health's strategies for viral hepatitis management include the prevention and early diagnosis of viral hepatitis infections; strengthening of the healthcare network and lines of treatment for sexually transmitted diseases, viral hepatitis, and AIDS; improvement and development of surveillance, information, and research; and promotion of universal access to medication. This review aims to summarize the available data on hepatitis C epidemiology and current status of efforts in prevention and infection control around the world and in Brazil.


Author(s):  
Prasanthi Polamreddy ◽  
Vinita Vishwakarma ◽  
Rambabu Gundla

Hepatitis C, a chronic disease affecting the global population significantly is caused majorly by Hepatitis C virus [HCV]. Among the several druggable targets explored for Hepatitis C, the viral protein, non-structural protein 5B [NS5B] is the target of choice for researchers as it is the key enzyme in the HCV replication and its active site is conserved among all genotypes. In the recent years the landscape of Hepatitis C therapies, have evolved from Peg-Interferon [PEG-INF]/Ribavirin, to directly acting anti-virus along with PEG-INF and finally, INF free regimens with greater than 90% sustained virological response [SVR]. The launch of Sofosbuvir, a nucleotide inhibitor of NS5B marks the major paradigm in hepatitis C research. Sofosbuvir exhibits, pan-genotypic activity, low barrier to resistance, highly effective and safe. However, the high prices of these medications limit their universal access. This review will focus on progress towards the discovery and development of NS5B inhibitors targeting allosteric sites and active site, covering the chemical class and structure-activity relationships.


2011 ◽  
Vol 7 (1) ◽  
pp. 39 ◽  
Author(s):  
Suerie Moon ◽  
Elodie Jambert ◽  
Michelle Childs ◽  
Tido von Schoen-Angerer

Sign in / Sign up

Export Citation Format

Share Document